Diagnostic and Therapeutic Applications of Microarrays in Liver Transplantation
Launched by UNIVERSITY OF ALBERTA · Jun 15, 2017
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The INTERLIVER trial is studying how the molecular characteristics of liver transplant biopsies relate to their physical appearance under a microscope and how this affects patient outcomes. In simpler terms, researchers want to understand how the genes in liver tissue samples can help doctors make better decisions about treating liver dysfunction after a transplant. They are looking for 300 liver transplant patients to participate in this study.
To be eligible for the trial, participants must be undergoing a biopsy for specific medical reasons related to their liver condition. Unfortunately, pregnant women cannot participate, and anyone who does not give consent will also be excluded. If you or a loved one joins the study, you can expect to provide a small sample of liver tissue during a routine biopsy, which will be used to learn more about the condition and improve future treatments. This research could lead to better care for liver transplant patients in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • biopsy for clinical indications
- Exclusion Criteria:
- • no consent, pregnant women
About University Of Alberta
The University of Alberta, a leading research institution in Canada, is dedicated to advancing healthcare through innovative clinical trials. With a strong commitment to scientific excellence and community health, the university facilitates cutting-edge research across various medical disciplines. Its interdisciplinary approach fosters collaboration among researchers, clinicians, and students, ensuring that clinical trials are designed and conducted with the utmost rigor and ethical standards. By leveraging its extensive resources and expertise, the University of Alberta aims to translate research findings into meaningful advancements in patient care and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Chicago, Illinois, United States
Baltimore, Maryland, United States
San Francisco, California, United States
Detroit, Michigan, United States
Nashville, Tennessee, United States
Dallas, Texas, United States
Richmond, Virginia, United States
Seattle, Washington, United States
Camperdown, , Australia
Edmonton, Alberta, Canada
Katowice, , Poland
Szczecin, , Poland
Warszawa, , Poland
Warszawa, , Poland
London, , United Kingdom
Patients applied
Trial Officials
Philip F Halloran, MD, PhD
Principal Investigator
University of Alberta
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials